Table 1 Patient demographics and baseline characteristics a (FAS, N = 138)
Donepezil | ||||
|---|---|---|---|---|
Placebo | 5 mg | 10 mg | Overall | |
Characteristics | ( n = 44) | ( n = 45) | ( n = 49) | ( n = 138) |
Sex, n (%) | ||||
Male | 17 (38.6) | 20 (44.4) | 21 (42.9) | 58 (42.0) |
Female | 27 (61.4) | 25 (55.6) | 28 (57.1) | 80 (58.0) |
Age, yr | 77.2 ± 6.1 | 78.8 ± 5.1 | 77.7 ± 6.8 | 77.9 ± 6.1 |
Weight, kg | 50.15 ± 10.75 | 50.68 ± 9.24 | 51.72 ± 9.89 | 50.88 ± 9.92 |
Duration of dementia, yr | 2.0 ± 2.3 | 2.7 ± 1.8 | 2.3 ± 1.9 | 2.3 ± 2.0 |
History of anti-dementia medication, n (%) | ||||
Yes | 1 (2.3) | 3 (6.7) | 4 (8.2) | 8 (5.8) |
No | 43 (97.7) | 42 (93.3) | 45 (91.8) | 130 (94.2) |
Cognitive fluctuation, n (%) | ||||
Yes | 40 (90.9) | 41 (91.1) | 46 (93.9) | 127 (92.0) |
No | 4 (9.1) | 4 (8.9) | 3 (6.1) | 11 (8.0) |
Visual hallucinations, n (%) | ||||
Yes | 42 (95.5) | 39 (86.7) | 39 (79.6) | 120 (87.0) |
No | 2 (4.5) | 6 (13.3) | 10 (20.4) | 18 (13.0) |
Parkinsonism, n (%) | ||||
Yes | 38 (86.4) | 39 (86.7) | 44 (89.8) | 121 (87.7) |
No | 6 (13.6) | 6 (13.3) | 5 (10.2) | 17 (12.3) |
Hoehn and Yahr stage, n (%) | ||||
I | 4 (9.1) | 8 (17.8) | 7 (14.3) | 19 (13.8) |
II | 15 (34.1) | 17 (37.8) | 19 (38.8) | 51 (37.0) |
III | 19 (43.2) | 14 (31.1) | 18 (36.7) | 51 (37.0) |
MMSE score | 20.3 ± 4.2 | 20.6 ± 4.1 | 20.3 ± 4.8 | 20.4 ± 4.3 |
NPI-2 score | 6.9 ± 4.5 | 6.9 ± 4.5 | 7.3 ± 4.7 | 7.1 ± 4.5 |
NPI-10 score | 20.5 ± 15.0 | 18.9 ± 15.3 | 16.6 ± 11.7 | 18.6 ± 14.0 |
ZBI score | 28.4 ± 16.2 | 28.3 ± 18.5 | 31.4 ± 17.8 | 29.4 ± 17.4 |